Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP & PRES GLOBAL ALLERG AESTH | May 11, 2023 | May 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date May 11, 2023 · Filed May 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 28,024 |
Reported balance
After 2023-05-11 transaction · row 1
1 source rowRow 1 · 2023-05-11 · Tax withholding · Disposed 2,876 · Balance 28,024 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2023 Filed May 12, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,876 | $146.42 | $421,103.92 |
DisclosureSEC source: 0001415889-23-007908 · form4-05122023_050501.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,024 Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 449 | $156.06 | $70,070.94 |
DisclosureSEC source: 0001415889-23-004428 · form4-03072023_050303.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,900 Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 810 | $155.27 | $125,768.70 |
DisclosureSEC source: 0001415889-23-003857 · form4-03022023_100349.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,349 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 5,762 | $154.28 | $888,961.36 |
DisclosureSEC source: 0001415889-23-003857 · form4-03022023_100349.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,159 Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 6,370 | $67.25 Strike: $67.25 | $428,382.50 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · derivative · entry 13 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,370 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 7,809 | $56.93 Strike: $56.93 | $444,566.37 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · derivative · entry 12 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,809 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 400 | $151.34 | $60,536.00 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 10 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,921 F8 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 567 | $150.78 | $85,492.26 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 9 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,321 F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 7,646 | $151.29 | $1,156,763.34 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 8 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,888 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,533 | $150.74 | $984,784.42 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 7 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,534 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 7,780 | $151.28 | $1,176,958.40 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 6 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,067 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,615 | $150.71 | $846,236.65 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 5 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,847 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 6,370 | $67.25 | $428,382.50 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 4 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,809 | $56.93 | $444,566.37 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 16,205 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · derivative · entry 11 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,205 Underlying: Common Stock · 16,205 shares Expires 2033-02-15 F9 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,402 on February 16, 2024, 5,402 on February 16, 2025, and 5,401 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,283 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,209 F1 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:46 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,876 | $152.09 | $437,410.84 |
DisclosureSEC source: 0001179110-22-003023 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,663 Read SEC document |
| May 07, 2022 Filed May 9, 2022 21:15 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 234 | $152.83 | $35,762.22 |
DisclosureSEC source: 0001179110-22-002934 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,539 Read SEC document |
| March 06, 2022 Filed Mar 7, 2022 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 355 | $150.56 | $53,448.80 |
DisclosureSEC source: 0001179110-22-002018 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,773 Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 448 | $150.56 | $67,450.88 |
DisclosureSEC source: 0001179110-22-002018 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,128 Read SEC document |
| March 02, 2022 Filed Mar 2, 2022 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 810 | $147.69 | $119,628.90 |
DisclosureSEC source: 0001179110-22-001925 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,576 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:15 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,840 | $149.54 | $424,693.60 |
DisclosureSEC source: 0001179110-22-001842 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,386 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption(Right to Buy) · Derivative | 24,080 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001520 · edgar.xml · derivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,080 Underlying: Common Stock · 24,080 shares Expires 2032-02-16 F2 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,027 on February 17, 2023, 8,027 on February 17, 2024, and 8,026 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001520 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,226 F1 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 4,184 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001179110-22-000922 · edgar.xml · derivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,184 shares Expires 2022-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,396 | $141.17 | $338,243.32 |
DisclosureSEC source: 0001179110-22-000922 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,499 Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,184 | $47.27 | $197,777.68 |
DisclosureSEC source: 0001179110-22-000922 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,895 Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 22:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 10,336 | $135.93 | $1,404,972.48 |
DisclosureSEC source: 0001179110-22-000262 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,711 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,057 | $120.00 | $606,840.00 |
DisclosureSEC source: 0001179110-21-008422 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,047 Read SEC document |
| May 11, 2021 Filed May 12, 2021 21:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,887 | $116.22 | $335,527.14 |
DisclosureSEC source: 0001179110-21-005245 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,104 Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 234 | $116.08 | $27,162.72 |
DisclosureSEC source: 0001179110-21-005196 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,991 Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:23 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 4,184 | $0.00 Strike: $41.39 | $0.00 |
DisclosureSEC source: 0001179110-21-004898 · edgar.xml · derivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,184 shares Expires 2021-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:23 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,184 | $112.40 | $470,281.60 |
DisclosureSEC source: 0001179110-21-004898 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,225 Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:23 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 4,184 | $41.39 | $173,175.76 |
DisclosureSEC source: 0001179110-21-004898 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2021 Filed Mar 9, 2021 22:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 123 | $106.70 | $13,124.10 |
DisclosureSEC source: 0001179110-21-003128 · edgar.xml · nonDerivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,225 Read SEC document |
| March 06, 2021 Filed Mar 9, 2021 22:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 356 | $106.70 | $37,985.20 |
DisclosureSEC source: 0001179110-21-003128 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,348 Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 448 | $105.65 | $47,331.20 |
DisclosureSEC source: 0001179110-21-003128 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,704 Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 01:25 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 810 | $108.41 | $87,812.10 |
DisclosureSEC source: 0001179110-21-002588 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,152 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 32,298 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002043 · edgar.xml · derivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,298 Underlying: Common stock · 32,298 shares Expires 2031-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,766 on February 18, 2022 10,766 on February 18, 2023, and 10,766 on February 18, 2024. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:02 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,576 | $107.15 | $276,018.40 |
DisclosureSEC source: 0001179110-21-000196 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,962 Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 23,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · nonDerivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,538 F3 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in four equal annual increments on the date of grant and include the right to have stock withheld for tax purposes. The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 3,613 | $0.00 Strike: $65.45 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 12 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2028-03-06 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. F6 · derivative.exercise_date: The options are exercisable as follows: 1,804 exercisable as of 5/8/2020; 902 as of 3/6/2021; and 907 as of 3/6/2022. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 3,440 | $0.00 Strike: $104.04 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 11 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,440 Underlying: Common Stock · 3,440 shares Expires 2027-03-06 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. F5 · derivative.exercise_date: The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 2,567 | $0.00 Strike: $123.51 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 10 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,567 Underlying: Common Stock · 2,567 shares Expires 2026-03-07 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 2,017 | $0.00 Strike: $133.53 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 9 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,017 Underlying: Common Stock · 2,017 shares Expires 2025-03-16 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 5,729 | $0.00 Strike: $125.82 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 8 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,729 Underlying: Common Stock · 5,729 shares Expires 2025-02-20 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 6,370 | $0.00 Strike: $67.25 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 7 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,370 Underlying: Common Stock · 6,370 shares Expires 2024-02-21 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 7,809 | $0.00 Strike: $56.93 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 6 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,809 Underlying: Common Stock · 7,809 shares Expires 2023-02-21 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 4,184 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 5 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,184 Underlying: Common Stock · 4,184 shares Expires 2022-02-17 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.